Summary of Significant Accounting Policies - Revenue Recognition, PPE, Licensing and Research (Details) - USD ($)	1 Months Ended		3 Months Ended								12 Months Ended
	Feb. 29, 2016	Oct. 31, 2014	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Research and Product Development
Product development and research costs			$ 2,126,397	$ 1,304,658	$ 1,675,494	$ 1,214,851	$ 1,200,729	$ 1,261,863	$ 2,063,324	$ 1,314,430	$ 6,321,400	$ 5,840,346	$ 4,961,313
Investments Available for Sale
Fair value of investments			24,648,459				40,759,703				24,648,459	40,759,703
Realized gains											$ 12,927	156,461
Licensing Fees
Useful life											17 years
Research and Development
Research and Development Expense			$ 2,126,397	$ 1,304,658	$ 1,675,494	$ 1,214,851	$ 1,200,729	$ 1,261,863	$ 2,063,324	$ 1,314,430	$ 6,321,400	5,840,346	4,961,313
Minimum
PROPERTY AND EQUIPMENT
Useful life											3 years
Maximum
PROPERTY AND EQUIPMENT
Useful life											10 years
Wanbang Biopharmaceutical
Revenue Recognition
Upfront payment	$ 4,000,000
Deferred drug license revenue											$ 200,000
Baxter Healthcare Organization
Revenue Recognition
Deferred drug license revenue											$ 2,099,028	$ 2,065,785	$ 2,081,668
Initial Payment Received		$ 20,000,000